SEC Form 4 · accession 0001127602-19-003737
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yarlagadda S Babu
Officer — Senior VP - Drug Discovery
Period of report
Jan 31, 2019
Accepted (ET)
Feb 4, 2019 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 31, 2019 | M | 19,686 | $1.20 | A | 127,786 | D | |
| Common StockF1 | Jan 31, 2019 | F | 7,702 | $8.68 | D | 120,084 | D | |
| Common Stock | Jan 31, 2019 | M | 12,188 | $1.20 | A | 132,272 | D | |
| Common StockF2 | Jan 31, 2019 | F | 1,685 | $8.68 | D | 130,587 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option | $1.20 | Jan 31, 2019 | M | 19,686 | D | Mar 2, 2010 | Mar 2, 2019 | Common Stock | 19,686 | 0 | D |
| Emp. Stock Option (Right to Buy) | $1.20 | Jan 31, 2019 | M | 12,188 | D | Mar 2, 2010 | Mar 2, 2019 | Common Stock | 12,188 | 0 | D |
Explanation of responses
- F1Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise.
- F2Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise.